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Ischaemiaion (POAF) is a common complication of cardiac surgery that occurs in up to 60%
of patients. POAF is associated with increased risk of cardiovascular mortality, stroke and other arrhythmias that
can impact on early and long term clinical outcomes and health economics. Many factors such as disease-induced
cardiac remodelling, operative trauma, changes in atrial pressure and chemical stimulation and reﬂex sympathet-
ic/parasympathetic activationhavebeen implicated in thedevelopment of POAF. There ismounting evidence to sup-
port amajor role for inﬂammation and oxidative stress in the pathogenesis of POAF. Both are consequences of using
cardiopulmonary bypass and reperfusion following ischaemic cardioplegic arrest. Subsequently, several anti-
inﬂammatory and antioxidant drugs have been tested in an attempt to reduce the incidence of POAF. However, pre-
vention remains suboptimal and thus far none of the tested drugs has provided sufﬁcient efﬁcacy to bewidely intro-
duced in clinical practice. A better understanding of the cellular andmolecularmechanisms responsible for the onset
and persistence of POAF is needed to develop more effective prediction and interventions.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
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. This is an open access article underdeterioration of mechanical function (Potpara & Lip, 2011; Andrade
et al., 2014; Weijs et al., 2014). Post-operative AF (POAF) is a common
complication (typically occurring within the ﬁrst 2 to 3 days) after car-
diac surgery with an incidence up to 60% depending on the type of sur-
gery (coronary artery bypass graft surgery, valve surgery, or combined)
(Maisel et al., 2001; Ascione et al., 2002; Mostafa et al., 2012;
Orenes-Pinero et al., 2012; Hernandez-Romero et al., 2014). Patients
with POAF have increased risk of cardiovascular mortality, stroke and
other arrhythmias than patients without POAF (El-Chami et al., 2010;
Mostafa et al., 2012; Brooks & Schindler, 2014; Philip et al., 2014).
Pre-existing co-morbidities, operative trauma, ischaemia and re-
perfusion injury during surgery, changes in atrial pressure due to
postoperative ventricular stunning, chemical stimulation and reﬂex
sympathetic/parasympathetic activation have all been identiﬁed as
contributing factors (Maisel et al., 2001; Ferro et al., 2009; Maesen
et al., 2012; Mostafa et al., 2012). The incidence of POAFdiffers betweenthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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pends on processes triggered by the surgical intervention itself (Creswell
et al., 1993). However, little is known about the cellular and molecular
mechanisms responsible for the onset or perpetuation of POAF. What is
known however is that POAF has some pro-arrhythmic mechanisms in
common with other forms of AF as supported by data demonstrating
that patients who develop POAF have a degree of structural remodelling
evident by a larger left atrium, a tendency towards having larger
left atrial appendage dimension, and lower left atrial ejection fraction. Ad-
ditionally, those patients tend to have increased atrial conduit function,
and evidence of left ventricular diastolic relaxation impairment compared
to those without AF (Aytemir et al., 1999; Nakai et al., 2002; Leung et al.,
2004; Ferro et al., 2009; Maesen et al., 2012; Nardi et al., 2012). Other ab-
normalities that have been associated with increased incidence of POAF
include high pre-operative levels of cholesterol (Aydin et al., 2014). Rele-
vant to this is the ﬁnding that metabolic syndrome (MS) is an indepen-
dent predictor of POAF (Brown & Moukdar, 2013; Hurt et al., 2013;
Montaigne et al., 2013).MS represents a cluster ofmetabolic events relat-
ed to various degrees of insulin resistance such as central obesity and hy-
pertension, thus increased risk of developing type 2 diabetes mellitus.
Mitochondrial dysfunction in patients withMS has been linked to the de-
velopment of arrhythmias (Montaigne et al., 2013), possiblymediated by
increased sensitivity to calcium-induced mitochondrial permeability
transition pore (mPTP) opening.
Finally, POAF has in recent years been closely linked to pro-
inﬂammatorymediators and oxidative stress. The level of inﬂammation
and oxidative stress is related to the pre-operative status and to the
triggers associated with cardiac surgery (Fig. 1). This review will focus
on the role of inﬂammation and oxidative stress in the pathogenesis of
POAF and their potential as therapeutic targets.
2. Origins of inﬂammatory response during open heart surgery
The inﬂammatory response during cardiac surgery is largely due
to the operative trauma involving surgery, CPB and organ reperfusion
injury. However, a less known source of inﬂammatory response is
associated pre-operative cardiovascular disease state.
2.1. Inﬂammatory state prior to surgery
Patients undergoing open heart surgery are likely to have a pre-
operative chronic inﬂammatory state that can be triggered by cardiac dis-
ease and co-existing co-morbidities. For example there is a close link be-
tween atherosclerosis and inﬂammation where atherosclerosis is
considered an inﬂammatory disease (Anogeianaki et al., 2011). Further-
more, there is strong experimental evidence to suggest that atherogenicFig. 1. Flow chart showing the source of inﬂammation & oxidative stress pre-and postop-
eratively. See text for details.stimuli (e.g., diabetes, dyslipidaemia) do in fact trigger vascular inﬂam-
matory response which indirectly contributes to stable atherosclerotic
disease and that plaque disruption is triggered by subsequent inﬂamma-
tory stimuli (Libby & Crea, 2010; Libby, 2012). The source of the inﬂam-
matory response is not necessarily systemic as ischaemic disease-
induced cardiac remodelling can in principle produce a local inﬂammato-
ry response as supported by work showing that hypoxic cardiomyocytes
produce cytokines (Sawa et al., 1998). One reason for the fact that this
chronic disease-related inﬂammatory response has not receivedmuch at-
tention from the scientiﬁc community could be the relatively low levels of
circulating inﬂammatory markers. However, this is likely to be more rel-
evant following an acute infarction as has been demonstrated in experi-
mental models (Deten et al., 2002; Deten & Zimmer, 2002). In clinical
settings, cytokines including IL6 are acutely elevated during ST- or non-
ST-elevation acute coronary syndromes (Neumann et al., 1995; De Servi
et al., 2014). Markers of inﬂammation are also elevated in heart failure
which can be reduced by cardiac resynchronization therapy (Rubaj
et al., 2013).
2.2. Systemic Inﬂammatory response during surgery
The main inﬂammatory response seen during cardiac surgery (both
systemic and non-systemic) is associated with the surgery itself. An
acute systemic inﬂammatory response is initiated by a number of injuri-
ous processes including surgical trauma, CPB andorgan reperfusion injury
(Paparella et al., 2002). CPB is a major trigger of inﬂammatory response
during cardiac surgery since off-pump surgery has been shown to signif-
icantly reduce inﬂammatory response (e.g. (Ascione et al., 2000; Caputo
et al., 2002; Nesher et al., 2006)). CPB can impact upon the cellular and
non-cellular elements of blood resulting in the activation of different
pro-inﬂammatory cascades (Hill, 1998; Anselmi et al., 2004;
Khoynezhad et al., 2004; Rinder, 2006; Suleiman et al., 2008). It is now
generally accepted that CPB is a direct trigger of cardiac injury since min-
iaturized cardiopulmonary bypass is associated with less cardiac injury
compared to conventional bypass (Remadi et al., 2006; Skrabal et al.,
2007; El-Essawi et al., 2010; Nguyen et al., 2014).More importantly, min-
iaturized cardiopulmonary bypass is associated with less inﬂammatory
response (van Boven et al., 2004; Remadi et al., 2006; Skrabal et al.,Fig. 2. Flow chart showing the effect of CPB and ischaemia and reperfusion on cardiac re-
modelling that can lead to POAF.
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mia, haemodilution, electrolyte imbalance, pharmacological agents used
during surgery have also been implicated in initiating inﬂammatory re-
sponses and triggering tissue injury (Asimakopoulos, 2001; Levy &
Tanaka, 2003; Iriz, 2004; Rinder, 2006). However, myocardial ischaemic
cardioplegic arrest and reperfusion has been implicated as amajor trigger
of tissue damage and inﬂammatory response (Fig. 2).
2.3. Inﬂammatory response associated
with myocardial ischaemia and reperfusion
Cardiomyocytes exposed to ischaemia–reperfusion or hypoxia–
reoxygenation produce IL-6 (Sawa et al., 1998; Chandrasekar et al.,
1999). This cytokine is also produced by themyocardium during ischae-
mic cold cardioplegic arrest in an experimental model of cardiopulmo-
nary bypass (Dreyer et al., 2000). Myocardial release of IL6 can be seen
during cardiac surgery on CPB as early as 10 min after reperfusion and
this release continues and increases throughout the reperfusion period
(Zahler et al., 1999). It is suggested that cardiac endothelial cells or mac-
rophages are responsible for early release whilst cardiomyocytes could
be responsible for latter release. Other pro-inﬂammatory cytokines pro-
duced by the heart during cardiac insults include IL-18 and IL-1β
(Matsumori et al., 1999; Pomerantz et al., 2001). IL-1 is produced in re-
sponse to local or systemic stimuli (Dinarello et al., 2012) and is respon-
sible for cardiac dysfunction in heart failure and the effect ismediated by
IL-18 (Toldo et al., 2014). It is also important to note that heart cells pro-
duce IL-10 (Jones et al., 2001). This is an anti-inﬂammatory cytokine in-
volved in the limitation and termination of inﬂammatory responses
(Asadullah et al., 2003). It is evident therefore that the myocardium is
a source of pro- and anti-inﬂammatory markers particularly during is-
chaemia and reperfusion. In addition to systemic inﬂammatory response
contributing to cardiac injury (see above), there is also mounting evi-
dence showing that this response (systemic and/or cardiac origin) can
directly alter cardiac function, possibly mediated by the action of cyto-
kines on membrane receptors of cardiomyocytes.
3. Inﬂammatory response and the
pathogenesis of postoperative atrial ﬁbrillation
3.1. The effect of inﬂammatory mediators on cardiac function
The effects of cytokines will depend on whether they are pro-
inﬂammatory or anti-inﬂammatory ones. It has been suggested that
IL-6 is capable of modulating cardiovascular function by a variety of
mechanisms, including promotion of left ventricular remodelling
(Pagani et al., 1992), induction of contractile dysfunction (Yokoyama
et al., 1993), and altering the response of myocardial β-adrenergic
receptors (Gulick et al., 1989).More importantly, IL-6 has been associated
with negative inotropic effects (Finkel et al., 1992) and myocardial stun-
ning (Zahler et al., 1999). These effects could be due to enhanced produc-
tion of nitric oxide (NO) and elevated cGMP (Stangl et al., 2002) which
would inhibit voltage dependent Ca2+ channels (Kojda et al., 1999).
Others (Dreyer et al., 2000) have implicated IL-6 in cardioprotection by
inhibiting cardiacmyocyte apoptosis. Other inﬂammatory cytokines, par-
ticularly IL-8, can exacerbate cardiac injury by enhancing leukocyte acti-
vation and accumulation. In fact, postoperative levels of cardiac troponin-
I have been shown to correlate with IL-8 levels in patients undergoing
CABG surgery (Wan & Yim, 1999). Another cytokine, IL-18 has been
shown to activate pro-apoptotic signalling pathways and induces endo-
thelial cell death (Chandrasekar et al., 2004). The heart is also inﬂuenced
by the anti-inﬂammatory cytokine IL-10 where its deﬁciency enhances
the inﬁltration of neutrophils into the myocardium (Jones et al., 2001).
It is evident that several of the inﬂammatory mediators generated in re-
sponse CPB and ischaemia–reperfusionwould contribute to cardiac func-
tional depression and apoptosis (Wang et al., 2005). These cardiac
changes could alter electrical activity and trigger arrhythmias.3.2. Inﬂammatory response and factors that
alter incidence of postoperative atrial ﬁbrillation
There is mounting evidence to support the inﬂuence of a surgery-
related acute inﬂammation on the pathogenesis of POAF. This is largely
based on association between levels and activity of white blood cells
and incidence of POAF. Patients who have higher postoperative leuko-
cytes count are signiﬁcantly more likely to develop POAF (Abdelhadi
et al., 2004; Lamm et al., 2006; Fontes et al., 2009; Sabol et al., 2012)
and patients developing POAF tend to have greater degree of mono-
cyte activation as seen by higher expression of CD11b (Fontes et al.,
2005). Moreover; the elevated pre and post-operative neutrophils/
lymphocytes ratio in patients undergoing CABG can be associated with
an increased incidence of POAF (Gibson et al., 2010). Exactly how
these blood components can trigger POAF is not known. Previous
work using animal models has shown that when activated neutrophils
bind to cardiac myocytes they can cause changes in myocyte electrical
activity that could be arrhythmogenic (B. F. Hoffman et al., 1997).
Ischaemic stress is potentially arrhythmogenic as supported by work
demonstrating that isopreternol-isoproterenol-induced atrial ischaemic
stress (fall in atrial ATP) produced a pro-arrhythmic substrate such that
atrial tachyarrhythmia could be induced by burst-pacing (S. J. Kim et al.,
2012).
CPB and surgical trauma can lead to the production of different pro-
inﬂammatory mediators alongside widespread endothelial activation
with increased expression of adhesion molecules and impaired release
of nitric oxide. Increased levels of IL-6, TNF-α and CRP have all been
associated with POAF (Ucar et al., 2007; Elahi et al., 2008; Wu et al.,
2013). Interestingly, eliminating the use of CPB (off pump) may not
fully attenuate the incidence of POAF (Place et al., 2002; Siebert et al.,
2003; Enc et al., 2004; Turk et al., 2007). This is likely to be due to the
fact that off pump surgery is also associated with acute inﬂammatory
responses as shown by increased post-operative levels of IL-6 and CRP
which remain predictive factors for the development of POAF in
patients undergoing off pump CABG (Ishida et al., 2006). Clearly, the
inﬂammatory response is not the onlymediator of POAF and the thresh-
old and the type of inﬂammatory response needed to augment inci-
dence of POAF is not presently known. In this respect it would be
interesting to ﬁnd out whether the incidence of POAF is also inﬂuenced
by valve surgery as ischaemic coronary disease (atherosclerosis) may
have a different effect on the inﬂammatory response. Ultimately, it is
the inﬂammatory response within the atrial tissue (remodelling) that
might be critical in determining the onset of POAF. When investigating
the expression of different pro-inﬂammatory markers in the left and
right atrial appendage it was noted that the intensity of VWF expression
in left atrial appendage tissue predicted patients who developed POAF
after CABG (Kaireviciute et al., 2011). TGF-β1 have also been implicated
in the pathology of AF in animal models. However, it is not known
whether this elevation is the trigger or the consequence of AF. Analysis
of human right atrial tissue has demonstrated the presence of higher
levels of total and active TGF-β1 in patients who developed POAF
compared to patients remaining in sinus rhythm. The impact of TGF-
β1on the development of POAF may be related to the possibility that
the factor can promote the expression of ﬁbrosis-related genes in a
Smad2 related pathway (Rahmutula et al., 2013). Hence, more work is
warranted in this area to establish whether atrial tissue inﬂammatory
response does in fact play an important role in the pathogenesis of
POAF. In particular it would be interesting to establish whether inﬂam-
mation triggers atrial remodelling and changes in Ca2+ cycling as both
these factors are implicated in triggering arrhythmias (Heijman et al.,
2014). It is interesting to note that the principal metabolite of the
ryanodine receptor modulator, K201, has an anti-arrhythmic action
against paroxysmal AF in the canine sterile pericarditis model of post-
operative AF associated with inﬂammation (Page et al., 1986; Kumagai
et al., 2004; Rossman et al., 2009; Zhang et al., 2011; Sadrpour et al.,
2015).
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Physiological redox signalling refers to the role of reactive oxygen
species (ROS) in intra- and intercellular communication (Collins et al.,
2012). Oxidative stress occurs when there is signiﬁcant uncontrolled
generation of ROS that overwhelm endogenous anti-oxidant capabili-
ties. Like inﬂammatory response (see above) pre-operative disease
states (e.g. ischaemia, diabetes, and atherosclerosis) are also associated
with oxidative stress (Giustarini et al., 2009). ROS are generated during
open heart surgery using CPB and CA. Main sources of elevated ROS are
associated with changes at both systemic and myocardial level.
4.1. Systemic reactive oxygen species production during surgery
The inﬂammatory response seen during CPB is in part responsible
for generating ROS and increased oxidative stress during cardiac
surgery (McDonald et al., 2014). It exposes RBCs to non-physiological
stimuli modifying their integrity and role. CPB can damage RBC due to
shear stress forces which make RBC less deformable and more fragile
(Hoffman, 1962; Morariu et al., 2004), thereby resulting in more free
Hb in circulation (Baskurt & Meiselman, 2003; Morariu et al., 2004;
Saraf et al., 2009; Zakkar et al., 2015). Furthermore; peri-operative
blood transfusion can result in increased oxidative stress when stored
blood is used due to diminish antioxidant properties or storage defect
which is evident from ATP and 2,3-diphosphoglycerate depletion and
increased lipid peroxidation (Relevy et al., 2008; Karkouti, 2012;
Zakkar et al., 2015).
4.2. Myocardial reactive oxygen species production during surgery
Although cardiomyocytes are considered a major source of ROS in
the injured myocardium, it is important to note that ROS can also be
generated by vascular endothelial cells and activated leukocytes involv-
ing NADPH oxidase and/or xanthine oxidase (Tsutsui et al., 2011). The
main trigger of ROS generation in the myocardium is reperfusion injury
(Suleiman et al., 2008; Suleiman et al., 2011). Ischaemia during cardiac
surgery is associated with reduced mitochondrial energy production
which can lead to changes in intracellular Na+, Ca2+ and pH
(Suleiman et al., 2001; Murphy & Steenbergen, 2008; Suleiman et al.,
2008). Ischaemic injury can lead to the accumulation of activated neu-
trophils in the myocardium resulting in the release ROS and other pro-
teolytic enzymes (Suleiman et al., 2008). Further myocardial damage
can occur during reperfusion as a consequence of mitochondrial dys-
function driven by ROS production (Wang et al., 2005; Suleiman et al.,
2011). The opening of the mPTP due to ROS production will result in
further ROS production and leads to mitochondrial swelling, mitochon-
drial membrane damage and cell death (Connern & Halestrap, 1994;
Halestrap et al., 2004; Honda et al., 2005; Pasdois et al., 2011).
Moreover; high ROS levels can modulate multiple signalling pathways
and transcription factors such as NF-KB, NRF2 and MAPK activation
leading to inﬂammation, apoptosis or necrosis (Barnes & Karin, 1997;
Grossmann et al., 1999; Grossini et al., 2009; Anedda et al., 2013).
4.3. Reactive oxygen species production and
the pathogenesis of postoperative atrial ﬁbrillation
Oxidative stress associated with CPB and CA is likely to trigger cellu-
lar changes in atrial tissue leading to disruption of electrical activity. The
main atrial remodelling that has been linked to the pathogenesis of
POAF is the ROS generating system, NADPH oxidase. Studies using
right atrial appendage samples from patients undergoing CABG sug-
gested that NADPH oxidase activity was the most important indepen-
dent predictor of developing POAF (Kim et al., 2005, 2008). NADPH
oxidases are a major source of ROS and have been implicated in parox-
ysmal and chronic AF (Kim et al., 2005; Wolke et al., 2014; Youn et al.,
2013). In ﬁbrillating myocardium, nitric oxide synthase can alsocontribute signiﬁcantly to basal, stimulated and NADPH-stimulated su-
peroxide release; suggesting that increased oxidative stress in this con-
dition may lead to nitric oxide synthase uncoupling (promoting
superoxide formation rather than nitric oxide) (Y. M. Kim et al., 2005).
Furthermore, signiﬁcant up-regulation of mitochondrial manganese su-
peroxide dismutase activity and an increased sensitivity of mPTP open-
ing have been demonstrated in atrial tissue frompatientswith triggered
POAF (Montaigne et al., 2013). Moreover; measuring total glutathione
(GSHt) and monoamine oxidase (MAO) in right atrial tissue suggested
that POAF risk was signiﬁcantly associated with MAO activity. In con-
trast, myocardial GSHt was inversely associated with POAF (Anderson
et al., 2014).
5. The role of anti-inﬂammatory agents and
anti-oxidants in reducing postoperative atrial ﬁbrillation
The fact that inﬂammation and oxidative stress can elicit POAF
has led to the undertaking of several trials using drugs with anti-
inﬂammatory and anti-oxidant properties to try to reduce the incidence
of POAF.
5.1. Statins
Statins (HMG-CoA reductase inhibitors) have proven to reduce
cardiovascular events in patients at risk for adverse outcomes by lipid-
lowering effects and anti-inﬂammatory and antioxidative stress proper-
ties (Liakopoulos et al., 2012). The ARMYDA-3 (Atorvastatin for Reduc-
tion of MYocardial Dysrhythmia After cardiac surgery) study recruited
200 patients undergoing elective cardiac surgery with CPB and showed
that treatment with atorvastatin 40 mg/day, initiated 7 days before
surgery signiﬁcantly reduced the incidence of POAF. Interestingly, the
study supported the notion that C-reactive protein (CRP) is closely
linked to POAF as patients who did not develop POAF had lower CRP
levels irrespective of randomization assignment (Patti et al., 2006). A
recentmeta-analysis of 54 trials incorporating 91,491 patients undergo-
ing cardiac surgery showed that preoperative statin use resulted in a
signiﬁcant reduction in early all-cause mortality, new onset POAF,
stroke and in-hospital stay (Kuhn et al., 2014). The exact mechanisms
involved in statin action are still not fully understood although statins
maymodulate post CPB inﬂammation; however, the evidence is not de-
ﬁnitive due to multiple limitations in study design such as protocols,
doses and the type of statin used (Kuhn et al., 2014).
5.2. Steroids
Multiple different clinical trials investigated the impact of steroids
administration on POAF and showed that it can signiﬁcantly reduce
pro-inﬂammatory responses and the incidence of POAF (Viviano et al.,
2014). Two meta-analysis of randomised clinical trials demonstrated
that corticosteroid prophylaxis can signiﬁcantly reduce the risk of
POAF and length of stay in the ICU, postoperative bleeding and major
wound infection compared with placebo (Whitlock et al., 2008; Ho &
Tan, 2009).
5.3. N-3-polyunsaturated fatty acids
In addition to anti-inﬂammatory interventions, several studies have
investigated the efﬁcacy of anti-oxidants in reducing the incidence of
POAF. Perioperative administration of n-3-PUFAs, such as those found
in ﬁsh oil, have been examined with regard to preventing cardiac ar-
rhythmias and sudden death. Although some trials had previously
shown favourable effect of such fatty acids on the incidence of POAF
(Calo et al., 2005; Sorice et al., 2011), recent multicentre double blind,
placebo controlled, clinical trial showed that perioperative supplemen-
tationwith n-3-PUFAs comparedwith placebo did not reduce the risk of
POAF (Mozaffarian et al., 2012). It is important to note that this study
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undergoing valvular surgery and patients with previous AF were
excluded in order to avoid any possible confounding factor and patients
in the n-3-PUFA group were hospitalized for signiﬁcantly fewer
days than those in the control group. Consequently, patients assigned
to n-3-PUFA may possibly have had asymptomatic episodes of AF after
discharge that were not identiﬁed. However; different meta-analysis
(Mariani et al., 2013; Mozaffarian et al., 2013; Zhang et al., 2014) have
conﬁrmed the ﬁnding of this trial and showed that perioperative sup-
plementation with n-3-PUFAs compared with placebo did not reduce
the risk of POAF.
5.4. Vitamins C & E
The administration of oral vitamin C peri-operatively to patients un-
dergoing CABG does not seem to be associated with reduced incidence
of POAF (Bjordahl et al., 2012). However when used in combination
with β-blockers, it was noted that it can favourably inﬂuence the inci-
dence of POAF (Eslami et al., 2007). A systematic literature review of 5
randomised controlled trials incorporating 567 patients showed that
the prophylactic use of vitamins C and Emay signiﬁcantly reduce the in-
cidence of POAF and all cause arrhythmia following cardiac surgery
(Harling et al., 2011). Of note, it has been reported that the combination
of n-PUFAs (2 g/day) (eicosapentaenoic acid: docosahexaenoic acid
ratio 1:2), vitamin C (1 g/day), and vitamin E (400 IU/day) can increase
the antioxidant potential, attenuating oxidative stress and inﬂamma-
tion and reducing the incidence of POAF (Rodrigo et al., 2013).
5.5. Colchicine
Colchicine is a medication used for treating gout, pericarditis, famil-
ial Mediterranean fever and Behçet's disease (Ben-Chetrit et al., 2006).
The anti-inﬂammatory effect of colchicine relates to its direct interac-
tion with microtubules, speciﬁcally the disruption of microtubules in
neutrophils (Andreu & Timasheff, 1982). Colchicine may exert effects
on cytokine provoked inﬂammation by diminishing the qualitative
expression of E-selectin on endothelium and the quantitative expres-
sion of L-selectin on neutrophils (Cronstein et al., 1995). In a randomised
controlled study investigating the effect of colchicine on the prevention
of early AF recurrence after pulmonary vein isolation, colchicine led to
signiﬁcant reductions in CRP and IL-6 levels compared to placebo
(Deftereos et al., 2012). Prolonged treatment with colchicine can
reduces IL-8, TNF-α and soluble E- and L-selectin levels in familial
Mediterranean fever patients (Kiraz et al., 1998). Furthermore; a study
in rats' renal tissue demonstrated that colchicine can prevent the in-
crease in TGF-β expression and apoptosis (Disel et al., 2004). A recent
multicentre randomized trial enrolled 360 patients undergoing cardiac
surgery with the primary end point being the occurrence of post-
pericardiotomy syndrome within 3 months and the main secondary
end points were postoperative AF and pericardial or pleural effusion.
This study showed that perioperative use of colchicine compared with
placebo reduced the incidence of post-pericardiotomy syndrome but
not of postoperative AF or postoperative pericardial/pleural effusion
(Imazio et al., 2014). Clearly whether colchicine can be used to reduce
POAF remains controversial.
5.6. N-acetylcysteine
Finally, the addition of the anti-oxidant n-acetylcysteine to
cardioplegia has been shown to reduce oxidative stress and coronary
endothelial activation (Rodrigues et al., 2009) and to decrease POAF
incidence in patients undergoing CABG surgery (Ozaydin et al., 2013).
This drug is a precursor to the amino acid cysteine which is a rate-
limiting factor in glutathione production. Inclusion of cysteine in the
perfusate of perfused rat heart has been shown to confer signiﬁcantcardioprotection and improved preservation of ATP and glutathione
(Shackebaei et al., 2005).
6. Conclusions
POAF is a common complication after cardiac surgery that can affect
patients' early and long term outcomes and use of hospital resources.
Inﬂammatory response and oxidative stress arising frompre-surgery ep-
idemiological factors, CPB and reperfusion injury contribute to the path-
ogenesis of the arrhythmia, although the precise cellular mechanisms
and pathways remain poorly resolved. Several anti-inﬂammatory agents
and anti-oxidants including statins, PUFAs, steroids, Colchicine, Vitamins
C and E, and acetylcysteine, have shown promising results in clinical tri-
als. However, morework is needed before they can be routinely included
in clinical practice. In particular, better understanding of atrial remodel-
ling during surgery and its role in thedevelopment of POAF is an essential
step towards developing more effective treatments and optimising con-
ditions for therapeutic interventions that are based on anti-inﬂammatory
agents and anti-oxidants.
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